Octapharma’s ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress

LACHEN, Switzerland, July 5, 2021 /PRNewswire/ — Octapharma announced today that new clinical and scientific findings encompassing their Haematology portfolio,…

LACHEN, Switzerland, July 5, 2021 /PRNewswire/ — Octapharma announced today that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on July 17–21, 2021.

In addition to two Supported Symposia that will discuss the comprehensive management of patients with haemophilia A and von Willebrand disease, seven ePosters will be presented covering a broad range of clinical research and ongoing initiatives to support the bleeding disorder community.

«Every day, our patients inspire us with their strength and resilience in navigating the challenges of living with a bleeding disorder. We are proud to share our most recent findings at ISTH 2021. The breadth of positive data across our Haematology portfolio demonstrate our ongoing efforts in addressing the differing unmet needs of patients with haemophilia and von Willebrand disease,» commented Larisa Belyanskaya, Head of IBU Haematology at Octapharma.

The symposium on von Willebrand disease, that takes place on Monday, July 19, chaired by Dr Fernando F. Corrales-Medina, follows one woman’s treatment journey with wilate® and will highlight key unmet needs of people who live with this challenging bleeding disorder. The international faculty will present and discuss recent data and ongoing studies on the management of heavy menstrual bleeding, pregnancy and childbirth, as well as management of perioperative bleeding in people with VWD.

On Tuesday, July 20, Dr Robert F. Sidonio Jr. will chair Octapharma’s symposium on haemophilia A, in which experts from around the world will present both clinical and scientific data from global collaborations on inhibitor management, factor VIII prophylaxis and important roles of factor VIII beyond haemostasis, aiming to support clinicians in making informed treatment decisions. 

Attendees will have the opportunity in both symposia to meet the speakers during live Q&A sessions, and both symposia will be available on-demand to participants after the Congress.

Olaf Walter, Board Member at Octapharma, stated that: «At Octapharma, we strive toward addressing the substantial challenges faced by people with bleeding disorders and to improve the lives of these individuals and their families. ISTH is an invaluable forum for engagement with key opinion leaders, experts, and the wider bleeding disorder community, and for sharing our expertise and research. Our contributions to ISTH 2021 underlie our long-standing commitment to every member of the bleeding disorder community.»

Supported Symposia

From Clinical Insights to Patient Experience: Suzanne’s Journey with von Willebrand Disease

Monday 19 July, 12:30–13:30 (EDT)

Chair: Dr Fernando F. Corrales-Medina, Division of Pediatric Hematology-Oncology, University of Miami-Miller School of Medicine, Miami, USA

Factor in the Future: Informed Treatment Decisions for Haemostasis and Beyond

Tuesday 20 July, 12:30–13:30 (EDT)

Chair: Dr Robert F. Sidonio Jr., Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Children’s Healthcare of Atlanta, Emory University, Atlanta, USA

ePosters

PB0502: Prospective, open-label, multicentre phase II study (PeKaFIX) to evaluate the pharmacokinetic parameters of a plasma derived factor IX concentrate and build a pharmacokinetic Bayesian model

PB0535: Long-term prophylaxis with simoctocog alfa in children

PB0549: Immunogenicity and safety of simoctocog alfa in previously treated patients switching to simoctocog alfa in the GENA clinical trial programme

PB0590: Efficacy of simoctocog alfa in previously untreated patients with severe haemophilia A: Final results from the NuProtect study

PB0627: PRactical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment with Nuwiq®, octanate® or wilate® – The Protect-NOW Study

PB0939: Plasma-derived VWF/FVIII concentrate (wilate®) for haemostasis in women with VWD during childbirth

PB0926: Don’t Let Bleeding Go Unnoticed – A Global Initiative to Increase Awareness of von Willebrand Disease

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 9,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology, and Critical Care.

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, and operates more than 160 plasma donation centres across Europe and the US.

For more information, please visit www.octapharma.com.

Logo – https://www.germanynewstoday.com/wp-content/uploads/2021/07/octapharmas-ongoing-dedication-to-improving-the-lives-of-people-with-haemophilia-and-von-willebrand-disease-to-be-showcased-at-the-isth-2021-congress-1.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/octapharmas-ongoing-dedication-to-improving-the-lives-of-people-with-haemophilia-and-von-willebrand-disease-to-be-showcased-at-the-isth-2021-congress-301325131.html

SOURCE Octapharma